| Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review W Shalata, A Abu-Salman, R Steckbeck, B Mathew Jacob, I Massalha, ... Cancers 13 (20), 5218, 2021 | 68 | 2021 |
| Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future CH Szeto, W Shalata, A Yakobson, A Agbarya Journal of Clinical Medicine 10 (23), 5614, 2021 | 27 | 2021 |
| A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors W Shalata, S Weissmann, S Itzhaki Gabay, K Sheva, O Abu Saleh, ... Cancers 14 (21), 5451, 2022 | 15 | 2022 |
| Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy I Polishchuk, A Yakobson, M Zemel, A A Sharb, W Shalata, E Rosenberg, ... Immunotherapy 13 (10), 807-811, 2021 | 15 | 2021 |
| Associated Myocarditis: A Predictive Factor for Response? W Shalata, N Peled, I Gabizon, O Abu Saleh, W Kian, A Yakobson Case Reports in Oncology 13 (2), 550-557, 2020 | 14 | 2020 |
| Molecular epidemiology and treatment patterns of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: the European EXOTIC Registry G Mountzios, D Planchard, G Metro, D Tsiouda, A Prelaj, S Lampaki, ... JTO clinical and research reports 4 (1), 100433, 2023 | 13 | 2023 |
| Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: a retrospective single-center study W Kian, M Zemel, EH Kestenbaum, K Rouvinov, W Alguayn, D Levitas, ... Medicine 101 (2), e28561, 2022 | 13 | 2022 |
| Crizotinib in MET exon 14-mutated or MET-amplified in advanced disease non-small cell lung cancer: a retrospective, single institution experience W Shalata, A Yakobson, S Weissmann, E Oscar, M Iraqi, W Kian, N Peled, ... Oncology 100 (9), 467-474, 2022 | 12 | 2022 |
| Adjuvant treatment with tyrosine kinase inhibitors in epidermal growth factor receptor mutated non-small-cell lung carcinoma patients, past, present and future W Shalata, BM Jacob, A Agbarya Cancers 13 (16), 4119, 2021 | 11 | 2021 |
| Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience W Shalata, J Zolnoorian, G Migliozzi, AA Jama, Y Dudnik, AY Cohen, ... International Journal of Molecular Sciences 24 (6), 5938, 2023 | 10 | 2023 |
| Vismodegib as first-line treatment of mutated sonic hedgehog pathway in adult medulloblastoma W Kian, LC Roisman, IM Goldstein, A Abo-Quider, B Samueli, N Wallach, ... JCO Precision Oncology 4, 437-441, 2020 | 10 | 2020 |
| Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer W Kian, P Christopoulos, AA Remilah, E Levison, E Dudnik, W Shalata, ... Frontiers in oncology 12, 1010311, 2022 | 9 | 2022 |
| Rapid response to the combination of lenvatinib and pembrolizumab in patients with advanced carcinomas (Lung adenocarcinoma and malignant pleural mesothelioma) W Shalata, M Iraqi, B Bhattacharya, V Fuchs, LC Roisman, AY Cohen, ... Cancers 13 (14), 3630, 2021 | 9 | 2021 |
| Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer: An … N Peled, LC Roisman, E Levison, J Dudnik, E Chernomordikov, ... International Journal of Radiation Oncology* Biology* Physics 117 (1), 105-114, 2023 | 7 | 2023 |
| Unexpected adverse events of immune checkpoint inhibitors W Shalata, A Yakobson, AY Cohen, I Goldstein, OA Saleh, Y Dudnik, ... Life 13 (8), 1657, 2023 | 7 | 2023 |
| Encephalitis induced by durvalumab during treatment of metastatic small-cell lung cancer: illustrative case and review of the literature Y Shechtman, W Shalata, R Khoury, A Mahajna, B Weller, A Agbarya Journal of Immunotherapy 44 (7), 243-247, 2021 | 6 | 2021 |
| Is alectinib-induced elevation of creatine phosphokinase a predictive factor for response? Report of two cases and review of the literature W Shalata, I Massalha, A Agbarya Anti-Cancer Drugs 32 (4), 456-459, 2021 | 6 | 2021 |
| Multi-center real-world outcomes of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non-small-cell lung cancer W Shalata, A Yakobson, Y Dudnik, F Swaid, MS Ahmad, A Abu Jama, ... Biomedicines 11 (9), 2438, 2023 | 5 | 2023 |
| Real-world experience in treatment of patients with non-small-cell lung cancer with Braf or Cmet exon 14 skipping mutations U Janzic, W Shalata, K Szymczak, R Dziadziuszko, M Jakopovic, ... International Journal of Molecular Sciences 24 (16), 12840, 2023 | 5 | 2023 |
| PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma A Yakobson, A Abu Jama, O Abu Saleh, R Michlin, W Shalata Cancers 15 (16), 4041, 2023 | 5 | 2023 |
